A Phase 2 study of ONO-4538 in patients with stage IIIB/IV or recurrent non-squamous NSCLC

Trial Profile

A Phase 2 study of ONO-4538 in patients with stage IIIB/IV or recurrent non-squamous NSCLC

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 15 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2018.
    • 09 Sep 2015 Pooled analysis results of this and other phase II (JapicCTI-No.132072) trial presented at the 16th World Conference on Lung Cancer.
    • 02 Jun 2015 Results of pooled analysis of two phase II trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top